Cart
×
WAVE Open Letter to Community
WAVE Open Letter to Community
The Phase 3 PolarisDMD Trial Goes Global
With a flurry of recent activity, 17 trial sites are now open for enrollment. We are especially excited to share that our first international sites in Canada and Australia have […]
Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053)
SRPT press release – golodirsen NDA acceptance 02 14 19
UT Southwestern Wellstone Symposium
We are excited about the UT Southwestern Wellstone Symposium on March 30! Don’t forget to RSVP by March 1. We’ll see you there! [download id=”13142″ template=”UT Southwestern Wellstone Symposium “]
UT Southwestern President’s Lecture Series – Gene Therapy and Gene Editing
Thursday February 28th at 4pm Dr. Eric Olson is giving a talk at the President’s Lecture at UT Southwestern (South Campus Gooch Auditorium) and will be highlighting the DMD project. Steve […]
NS Pharma Community Letter
We are excited that our industry partner, NS Pharma, has applied for accelertated approval for it’s exon 53 skipping therapy, viltolarsen. We applaud the dedication to the Duchenne community by […]
New Year Letter – Santhera to DMD Community
We’re pleased to share this letter and news from our partner Santhera about their plans for 2019! For more than 10 years, Santhera has been working on treatments for DMD, […]
World Muscle Society: Day 3 Highlights
Highlights from day three at the World Muscle Society meeting in Mendoza, Argentina, provided by CureDuchnne’s scientist, Dr. Mike Kelly. Mallinckrodt Pharmaceuticals Mallinckrodt provided an update on their Phase 2 […]
World Muscle Society: Day 2 Highlights
Highlights from day two at the World Muscle Society meeting in Mendoza, Argentina, provided by CureDuchnne’s scientist, Dr. Mike Kelly. Sarepta’s Gene Therapy Program: Sarepta provided a much-anticipated update on […]